Jason McCarthy
Jason McCarthy, Ph.D., is an equity research analyst covering the biotechnology industry at Maxim Group. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in biomedical sciences from the Albert Einstein College of Medicine. McCarthy also holds master's degrees in both biomedical research (Albert Einstein College of Medicine) and molecular biology (Adelphi University), as well as a bachelor's degree in biochemistry from Stony Brook University. He closely follows gene therapy, CAR-T and the cancer immunology spaces, as well as many traditional biotechnology companies.
Recent Quotes
"We initiate coverage on AWKNF with a Buy rating."
—
Jason McCarthy, Maxim Group
(9/1/21)
more >
"INO's vaccine showed 100% protection against the Lassa fever virus."
—
Jason McCarthy, Maxim Group
(10/24/17)
more >
"INO continues to advance multiple early-stage studies forward which should provide incremental catalysts as data emerges."
—
Jason McCarthy, Maxim Group
(10/16/17)
more >
"INO announced positive (Phase 1b) data for INO-5150."
—
Jason McCarthy, Maxim Group
(9/12/17)
more >
"INO is a pivotal company and multiple pipeline programs continue to advance."
—
Jason McCarthy, Maxim Group
(8/9/17)
more >
"While INO has continued to advance multiple earlier-stage DNA-based immunotherapies forward, providing incremental catalysts for the stock, our focus has remained on the start of the P3 program for VGX-3100 in high-grade cervical dysplasia."
—
Jason McCarthy, Maxim Group
(6/8/17)
more >
"INO announced a collaboration with Roche to evaluate their DNA-based immunotherapies in advanced bladder cancer."
—
Jason McCarthy, Maxim Group
(6/1/17)
more >
"INO's immune responses demonstrated by PENNVAX-GP are among the highest responses shown for an HIV vaccine."
—
Jason McCarthy, Maxim Group
(5/24/17)
more >
